Secondary malignant neoplasm of kidney and renal pelvis
ICD-10 C79.0 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of kidney and renal pelvis.
C79.0 refers to secondary malignant neoplasms that have metastasized to the kidney and renal pelvis from a primary cancer located elsewhere in the body. This condition is characterized by the presence of cancerous cells in the renal tissues, which can arise from various primary sites, including the lungs, breast, or gastrointestinal tract. The diagnosis of secondary malignant neoplasm of the kidney often indicates advanced disease and may present with symptoms such as hematuria, flank pain, or renal dysfunction. Staging of metastatic renal neoplasms is crucial for determining prognosis and treatment options, typically classified using the TNM system (Tumor, Node, Metastasis). Palliative care considerations are essential, as many patients may not be candidates for curative treatment due to the extent of disease. Management often focuses on symptom relief, quality of life, and supportive care, including pain management and psychosocial support. Accurate coding requires thorough documentation of the primary cancer site, staging details, and any palliative measures undertaken.
Detailed history of the primary cancer, staging information, and treatment history.
Patients presenting with renal symptoms who have a known history of cancer.
Ensure accurate documentation of the primary site and any treatments received.
Clinical findings from imaging studies, biopsy results, and renal function tests.
Patients with renal masses and a history of metastatic cancer.
Document any interventions performed, such as nephrectomy or palliative procedures.
Used when a biopsy is performed to confirm metastatic disease.
Pathology report confirming malignancy and origin.
Oncologists and pathologists must collaborate for accurate diagnosis.
Documenting the primary cancer site is crucial for accurate coding of secondary malignancies, as it impacts treatment decisions, prognosis, and reimbursement. Without clear documentation, there is a risk of misclassification and potential audit issues.
